Peak Bio, Inc.

Peak Bio, Inc.

$0.01
0 (0%)
NASDAQ
USD, US
Biotechnology

52 Week Range

0.002-1.0

Beta

0.15

Market Cap

$192.61K

Last Dividend

0

PE (TTM)

-0.01

Dividend Yield (TTM)

0

Price Chart

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Stephen LaMond M.B.A., Pharm.D., PharmD MBA

Full-Time Employees

21

IPO Date

2021-03-15

Description

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Phone

650-549-9103

Address

3350 W Bayshore Rd., Palo Alto, CA, 94303, US

CIK

0001834645